IRIS
TANDA, ENRICA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.049
Totale 1.049
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 1.049
Totale 1.049
Salva come PNG Salva come JPEG
Città #
Vado Ligure 317
Genova 279
Genoa 274
Rapallo 172
Bordighera 7
Totale 1.049
Salva come PNG Salva come JPEG
Nome #
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 152
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 78
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 71
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI) 65
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 63
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 58
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 50
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 49
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 43
How to make immunotherapy an effective therapeutic choice for uveal melanoma 40
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 35
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 31
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 31
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 27
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 25
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 23
Development of a gene panel for hotspot mutation and copy number alterations based uveal melanoma prognostication. 21
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 21
Primary endobronchial melanoma: a case report and clinical management indications 20
The treatment of advanced melanoma: Current approaches and new challenges 20
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 18
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 16
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 15
Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma 13
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 13
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 11
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 11
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 10
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms 9
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma 9
The adjuvant treatment revolution for high-risk melanoma patients 9
Current status and perspectives in immunotherapy for metastatic melanoma 8
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 7
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 7
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 7
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 6
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel 6
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 6
Machine Learning Methods for Gene Selection in Uveal Melanoma 4
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 4
Totale 1.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.337
article - articoli 6.276
book - libri 0
conference - conferenze 61
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.674
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202049 0 0 0 0 4 5 4 2 9 13 12 0
2020/202193 5 3 9 0 4 15 13 7 10 12 14 1
2021/2022104 11 1 3 10 5 5 2 19 6 23 3 16
2022/2023208 15 20 2 12 42 24 0 18 29 1 37 8
2023/2024246 8 12 9 28 14 50 14 7 12 20 11 61
2024/2025361 56 76 22 90 117 0 0 0 0 0 0 0
Totale 1.112